Alveolar Soft Part Sarcoma Market
Number of pages: 100 | Report Format: PDF | Published date: April 06, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
4.8% |
|
Base Year For Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Therapy, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global alveolar soft part sarcoma market is expected to register a revenue CAGR of 4.8% during the forecast period from 2023 to 2031.
Alveolar Soft Part Sarcoma Market Fundamentals
Alveolar soft part sarcoma (ASPS) is an extremely rare malignancy of unknown cellular origin, accounting for 1% of all soft tissue sarcomas. Alveolar soft part sarcoma characteristics include slow growth, minimal metastatic potential, and a propensity to return even after total surgical resection. With a high likelihood of spreading to the lungs and brain, alveolar soft part sarcoma usually affects adolescents and young adults. As the condition is asymptomatic most of the time, it remains undetected. Chemotherapy and targeted medicines like tyrosine kinase inhibitors are all possible alveolar soft part sarcoma treatments. The pathogenesis of alveolar soft tissue sarcoma seems to be resistant to chemotherapy. Due to its resistance to chemotherapy, this cancer is uncommon and challenging to treat. Antimetabolites, alkylating agents, mitosis inhibitors, anthracyclines, antimicrobials, antineoplastics, antifolates, COX-2 inhibitors, interleukin-2, interferon-alpha, and TNP-470 are few chemotherapeutic agents used to treat alveolar soft part sarcoma. Only 3% of patients responded to doxorubicin-based therapy, according to the largest report of outcomes from chemotherapeutic treatment in alveolar soft part sarcoma. Most chemotherapy patients experience illness progression with no partial or marginal responses. This demonstrates the need for alternative treatment choices and the limited effectiveness of chemotherapy in treating alveolar soft part sarcoma. As a result, the global alveolar soft part sarcoma market overview can be summated along the lines of factors such as an increasing interest in researching cutting-edge treatments for alveolar soft part sarcoma, such as immunotherapy and tailored therapy. These treatments have been the subject of hopeful clinical trials, raising the possibility that they could successfully treat this uncommon cancer type. The prominent alveolar soft part sarcoma market trends include more investigation to find more efficient treatments for this unique and aggressive tumor.
Alveolar Soft Part Sarcoma Market Dynamics
All cancer types have seen a rise in incidence over the past few decades. More than 60% of new cancer diagnoses globally are made in Africa, Asia, Central America, and South America, accounting for 70% of all cancer-related deaths. There is an urgent need for improved cancer prevention, early detection, and treatment in low and middle-income countries. These regions should have better access to cancer screening, vaccination campaigns, and cost-effective treatments. Thus, the factors such as the rising need for advanced cancer treatment support the global alveolar soft part sarcoma market demand. Unmet market pressures are a major chance for developing ground-breaking, first-in-class therapies. This change can be taken advantage of by spending money on the research and development of novel medications that can meet the alveolar soft part sarcoma market revenue growth, thereby improving patient outcomes and giving the pharmaceutical industry a competitive edge. To bring these therapies to market, this strategy needs a lot of money and dedication over the long term.
Moreover, a robust pipeline ensures enough fresh and potent medications are being created to treat alveolar soft tissue sarcoma, which raises the demand for these medications and propels the market revenue to grow. A robust pipeline also draws funding from pharmaceutical firms, further supporting market revenue growth. Seven of the 45 medicines in development for sarcoma are in Phase III trials, 22 are in Phase II, two are in Phase I/II studies, and the remaining 23 are in Phase I and pre-clinical trials. Additionally, two novel drugs are in phase II and III trials for alveolar soft part sarcoma. In multiple clinical trials, the potential function of immuno-oncology agents in alveolar soft part sarcoma is being investigated. A rising interest in creating efficient treatments for this condition is evidenced by the number of sarcoma-related drugs in development, particularly those in Phase III and II trials. According to the assessment of immuno-oncology drugs in Phase I/II clinical studies, a new class of treatments may soon be developed.
However, owing to poor healthcare infrastructure, a lack of funding, and low awareness, access to cancer care is frequently restricted in several countries, which are the major alveolar soft part sarcoma market challenges. Governments, healthcare providers, and international organizations must work together to address these issues to guarantee that everyone can access high-quality cancer treatment, regardless of the patient's income.
Alveolar Soft Part Sarcoma Market Ecosystem
The global alveolar soft part sarcoma market is analyzed from four perspectives: type, therapy, end user, and region.
Alveolar Soft Part Sarcoma Market by Type
[876687]
Based on the type, the global alveolar soft part sarcoma market is segmented into monotherapy and combination therapy.
The combination therapy segment accounted for the largest revenue share of the global alveolar soft part sarcoma market in 2022. Targeted treatment with immunotherapy may be more efficient for treating primary alveolar soft part sarcoma patients with advanced distant metastases. Combination therapy has recently proven to be the most successful treatment for alveolar soft part sarcoma. It is critical for those with advanced alveolar soft part sarcoma cases to keep looking into and creating new treatment choices. Most people with alveolar soft tissue sarcoma are reportedly resistant to conventional chemotherapy. Alternative treatment choices, such as targeted therapies, have produced encouraging outcomes. Patients with advanced distant metastases from primary alveolar soft tissue sarcoma may respond better to targeted therapy combined with immunotherapy. For instance, a clinical trial sponsored by National Cancer Institute evaluating the phase II trial studies how well atezolizumab or atezolizumab plus bevacizumab works in treating patients with alveolar soft part sarcoma. While immunotherapy strengthens the immune system to combat cancer cells, targeted therapies specifically target the molecules responsible for cancer cells' development and survival. Patients with alveolar soft part sarcoma who do not react to traditional chemotherapy may have better outcomes with these combination therapies.
Alveolar Soft Part Sarcoma Market by Treatment
Based on the therapies, the global alveolar soft part sarcoma market is segmented into chemotherapy, targeted therapy, and immunotherapy.
The targeted therapy segment accounted for the largest revenue share of the global Alveolar soft part sarcoma market in 2022. Standard cytotoxic chemotherapy, which is commonly used for treating soft-tissue sarcoma (STS), has a limited curative benefit in alveolar soft part sarcoma. Clinical studies involving alveolar soft part sarcoma patients with advanced or metastatic diseases revealed objective responses to multi-receptor tyrosine kinase inhibitors like sunitinib, pazopanib, and cediranib. Most multi-receptor tyrosine kinase inhibitors have a high response rate for alveolar soft part sarcoma. Patients with alveolar soft part sarcoma frequently needed to take their medications longer due to their great response to tyrosine kinase inhibitors. Choosing an appropriate dosage of the targeted agents is crucial to ensure the continuation of treatment and keep the therapeutic effect. In metastatic alveolar soft part sarcoma cases, the response rate to targeted therapy is clinically significant and on a level with first-line chemotherapy. Effective targeted therapy is also considered effective as a first line of defense for alveolar soft part sarcoma patients. Targeted therapy may also provide a less harmful substitute for conventional chemotherapy regimens, enhancing the quality of life for patients enduring treatment. Most patients who received targeted therapy had their illnesses under control. Patients with progressive or refractory illness to one targeted medication responded to other medications.
Alveolar Soft Part Sarcoma Market by End User
Based on the end users, the global alveolar soft part sarcoma market is segmented as hospitals, cancer specialty centers, homecare settings, and others.
The hospital's segment accounted for the largest revenue share of the global Alveolar soft part sarcoma market in 2022. The market has taken the lead as hospitals obtain more funding to invest in state-of-the-art, innovative care. This change has made the healthcare sector more competitive, with hospitals competing for patients and attempting to set themselves apart through cutting-edge technology and better patient outcomes. Patients now have more options and easier access to advanced medical procedures. However, hospitals are thought to be the ideal setting for cancer treatment. The most frequent side effects for which cancer patients visit hospitals for emergency care include pain, nausea, and loss of breath. Hospitals, therefore, account for the largest revenue share for the alveolar soft part sarcoma market due to frequent hospital visits. Additionally, hospitals receive significant funding and reimbursement policies for healthcare from various levels of government and business, making it simpler for patients to receive proper treatment regardless of their financial situation.
Alveolar Soft Part Sarcoma Market by Region
Based on the region, the global alveolar soft part sarcoma market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the largest revenue share of the global alveolar soft part sarcoma market in 2022. The primary factor fueling growth in markets in North America is the high prevalence of soft tissue and alveolar sarcomas in this continent. Additionally, rising expenditures in R&D efforts to create novel therapeutics and treatment options for alveolar soft tissue sarcoma are anticipated to spur market growth in North America further. Moreover, the main drivers of North America's market revenue growth are the development of invasive treatments, current FDA approval, and rising patient and physician adoption of innovative approaches.
Competitive Landscape of the Global Alveolar Soft Part Sarcoma Market
Notable market participants operating in the global alveolar soft part sarcoma market with the largest revenue share include,
Strategic Development in Alveolar Soft Part Sarcoma Market
Alveolar soft part sarcoma is a very uncommon, slow-growing, highly angiogenic tumor that can affect people of any age. It is most common in young adults and adolescents and usually starts in the lower extremities.
New treatment strategies and increased disease prevalence are the key trends to fuel global alveolar soft part sarcoma market revenue growth.
High cost and lack of awareness about alveolar soft part sarcoma are potentially restricting the revenue growth of the global alveolar soft part sarcoma market.
Key companies operating the global Alveolar soft part sarcoma market are Genor Biopharma Co. Ltd, Advenchen Laboratories LLC, Merck Sharp & Dohme LLC, Pfizer Inc., and Novartis AG, Takeda Pharmaceutical Company Limited.
The global alveolar soft part sarcoma market is expected to grow at a revenue CAGR of 4.8% during the forecast period from 2023 to 2031.
*Insights on financial performance are subject to the availability of information in the public domain